Amundi’s Crinetics Pharmaceuticals CRNX Stock Holding History

Amundi’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$351K	Sell	9,393 -3,641	-28%	-$135K	﹤0.01%	1790
2026 Q1	$473K	Buy	13,034 +7,412	+132%	+$331K	﹤0.01%	1565
2025 Q4	$262K	Buy	+5,622	New	+$250K	﹤0.01%	1685
2025 Q2	–	Sell	-57	Closed	-$1.65K	–	1784
2025 Q1	$1.65K	Buy	57 +5	+10%	+$187	﹤0.01%	1978
2024 Q4	$2.52K	Buy	+52	New	+$2.91K	﹤0.01%	1976
2024 Q2	–	Sell	-3,352	Closed	-$144K	–	1941
2024 Q1	$144K	Hold	3,352	–	–	﹤0.01%	1699
2023 Q4	$127K	Buy	3,352 +1,532	+84%	+$47K	﹤0.01%	1724
2023 Q3	$53K	Hold	1,820	–	–	﹤0.01%	1867
2023 Q2	$32.8K	Sell	1,820 -1,475	-45%	-$29.4K	﹤0.01%	1933
2023 Q1	$52.6K	Hold	3,295	–	–	﹤0.01%	1878
2022 Q4	$54.9K	Hold	3,295	–	–	﹤0.01%	1690
2022 Q3	$61K	Buy	+3,295	New	+$67.2K	﹤0.01%	1636

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's CRNX Position: Q2 2026 in Review

Amundi reduced its Crinetics Pharmaceuticals (CRNX) stake by 28% in Q2 2026, selling an estimated $135K and leaving 9,393 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

Amundi first reported a position in CRNX in Q3 2022 and has held it in 12 quarters since. The position peaked at $473K in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Amundi held 9,393 shares of Crinetics Pharmaceuticals worth $351K as of Q2 2026.
Amundi sold 3,641 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $135K.
Crinetics Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1790 holding.
Amundi first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
Amundi's Crinetics Pharmaceuticals position peaked at $473K in Q1 2026.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.